NIH awards $1.2M grant to project using AI to restore movement in paralyzed limbs

The National Institutes of Health has awarded a $1.2 million grant for a project aimed at restoring voluntary movement in paralyzed limbs using AI.

The grant was awarded to Andrew Fuglevand, PhD, a professor of physiology and neuroscience at the University of Arizona College of Medicine—Tucson. The grant funding will be used to study electrical stimulation of the muscles to restore limb movement in paralyzed individuals, according to a press release.

Fuglevand plans to use machine learning to mimic and replicate the patterns of brain activity that control groups of muscles, and implant tiny electrodes in the muscles that replay the artificially-generated signals and produce complex movements. The overall goal of the research is to restore voluntary movement for a paralyzed individual, without relying on external mechanical or robotic devices.

"Moving a finger involves as many as 20 different muscles at a time. Moving an arm can involve more than 50 different muscles. They all work together in an intricate 'dance' to produce beautifully smooth movements. Replicating how the brain naturally coordinates the activities of these muscles is extremely challenging," Fuglevand said in the release. “If successful, this approach would greatly expand the repertoire of motor behaviors available to paralyzed individuals.”

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.